Related Experiment Video

Updated: Mar 18, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Immune checkpoint inhibitor therapy for gastric cancer: current status, therapeutic challenges, and future prospects

Penghui Liu1, Na Li1, Jiwu Guo1

  • 1Lanzhou University Second Hospital, The General Surgery Department, Lanzhou, China.

Frontiers in Immunology
|March 16, 2026
PubMed

Insights

Immune checkpoint inhibitors (ICIs) show promise for gastric cancer treatment by boosting immune responses. However, challenges like resistance and side effects necessitate further research for personalized immunotherapy strategies.

Area of Science:

  • Oncology
  • Immunology
  • Gastroenterology

Background:

  • Gastric cancer is a leading digestive system malignancy globally.
  • Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 pathways have advanced gastric cancer treatment.
  • Despite progress, significant challenges impede ICI efficacy in gastric cancer.

Purpose of the Study:

  • To review recent advances in ICI-based gastric cancer therapies.
  • To analyze current clinical challenges associated with ICIs.
  • To highlight future research directions for optimizing gastric cancer immunotherapy.

Main Methods:

  • Narrative review of current literature on ICIs in gastric cancer.
  • Analysis of therapeutic resistance, adverse events, biomarkers, and tumor microenvironment.
  • Identification of key areas for future research and development.

Main Results:

  • ICIs offer novel therapeutic options by enhancing antitumor immunity.
  • Key challenges include therapeutic resistance, immune-related adverse events, lack of biomarkers, and immunosuppressive tumor microenvironment.
  • Future directions involve biomarker discovery, predictive models, combination regimens, resistance targeting, microbiota modulation, and toxicity management.

Conclusions:

  • Advancing gastric cancer immunotherapy requires addressing current challenges.
  • Future efforts should focus on individualized, precision-based approaches for maximum efficacy and safety.
  • Optimizing ICI therapy holds potential for significant breakthroughs in gastric cancer treatment.
Keywords:
efficacy and safetygastric cancerimmune checkpoint inhibitorsimmunotherapypersonalized treatment

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.6K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.6K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
723
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
612